Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Taha SenJingwei LiBrendon L NeuenBruce C NealClare ArnottChirag R ParikhSteven G CocaVlado PerkovicKenneth W MahaffeyYshai YavinNorman RosenthalMichael K HansenHiddo J Lambers HeerspinkPublished in: Diabetologia (2021)
Canagliflozin decreased KIM-1 and modestly reduced TNFR-1 and TNFR-2 compared with placebo in individuals with type 2 diabetes in CANVAS. Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of kidney disease progression, suggesting that TNFR-1 and TNFR-2 have the potential to be pharmacodynamic markers of response to canagliflozin.